InvestSMART

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $9.780 -2.55 (-20.68%)+
Announcement
Release
8 Dec 2025 8:33AM
Price at Release
$12.330
Full Release
download
Summary
Clinuvel Pharmaceuticals Limited announced the expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore, aiming to establish it as a global hub for developing advanced peptide therapies. Supported by the Singapore Economic Development Board, this five-year strategic investment will enhance the centre's capabilities in formulation and analytical sciences, focusing on liquid controlled-release drug products. This expansion is part of Clinuvel's broader strategy of innovation in peptide-based medicine, ensuring ongoing projects continue smoothly while positioning the company as a leader in peptide delivery technologies.
Key Points
  • Clinuvel announces expansion of VALLAURIX RD&I Centre in Singapore.
  • The expansion focuses on developing advanced, long-acting peptide therapies.
  • Supported by the Singapore Economic Development Board (EDB).
  • Five-year strategic investment aimed at global innovation in peptide-based medicine.
  • VALLAURIX Centre to enhance formulation and analytical capabilities.
  • Expansion aligns with Clinuvel's strategy of vertical integration and innovation.
  • Ongoing projects in pharmaceutical formulations to continue without disruption.
  • Expansion aims for full commissioning and certification by FY2028.
  • The initiative places Clinuvel at the forefront of peptide delivery technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.